← All trials
NCT06759636
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2025
- Primary completion
- Apr 21, 2026
- Completion date
- Jul 21, 2026
- First posted
- Jan 6, 2025
- Last posted
- Jan 6, 2025
- Enrollment
- 88
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Medical UniversityLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.